Jardiance under the microscope: new study tracks heart failure outcomes in china
NCT ID NCT07047508
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 20 times
Summary
This study will observe about 3,000 adults in China with heart failure with preserved ejection fraction (HFpEF) who are starting the drug Jardiance. Researchers will track how often patients are hospitalized for heart failure or die from heart-related causes. The goal is to see how well the drug works and how safe it is in everyday medical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.